Hydroxylases as therapeutic targets in inflammatory bowel disease

Laboratory Investigation

Volumn 93, Issue 4, 2013, Pages 378-383

  Cummins, Eoin P ^a   Doherty, Glen A ^a   Taylor, Cormac T ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Crohn's disease; DMOG; epithelial barrier; therapeutics; ulcerative colitis

Indexed keywords

DMOG; FG 4497; GASTROINTESTINAL AGENT; UNCLASSIFIED DRUG;

APOPTOSIS; CROHN DISEASE; DRUG MECHANISM; ENTERITIS; GENE EXPRESSION; HYPOXEMIA; HYPOXIA; INFLAMMATION; INTESTINE EPITHELIUM CELL; NEUTROPHIL; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN SENSING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ULCERATIVE COLITIS;

ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; MIXED FUNCTION OXYGENASES; MOLECULAR TARGETED THERAPY;

EID: 84875758986     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.9     Document Type: Review

References (73)

1. Wilks S. Morbid appearances in the intestines of Miss Bankes. Med Times Gazette 1859;2:264-265.
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365: 1713-1725.
3. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med 2000;67:263-268.
4. Abraham C, Cho J. Inflammatory bowel disease. N Engl J Med 2009;361:2066-2078.
5. Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol 2012;18:3790-3799.
6. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140: 1785-1794.
7. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54 e42, quiz e30.
8. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011;140:1704-1712.
9. Kenny EE, Pe'er I, Karban A, et al. A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet 2012;8:e1002559.
10. Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011;43:1066-1073.
11. Hugot JP, Zaccaria I, Cavanaugh J, et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol 2007;102:1259-1267.
12. Ruland J. CARD9 signaling in the innate immune response. Ann N Y Acad Sci 2008;1143:35-44.
13. Zhu L, Lee P, Yu D, et al. Cloning and characterization of human MUC19 gene. Am J Respir Cell Mol Biol 2011;45:348-358.
14. Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1090-1100.
15. Yang H, Minamishima YA, Yan Q, et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 2007;28:15-27.
16. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-429.
17. Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011;27: 346-357.
18. Perrier C, Rutgeerts P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy 2011;3:1341-1352.
19. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am 2009;38:577-594.
20. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285.
21. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409-1422.
22. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9:36-41 e1.
23. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619-1635.
24. Cohen BL, Torres J, Colombel JF. Immunosuppression in inflammatory bowel disease: how much is too much? Curr Opin Gastroenterol 2012; 28:341-348.
25. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-241.
26. Glover LE, Colgan SP. Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis. Gastroenterology 2011; 140:1748-1755.
27. Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004;114:1098-1106.
28. Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol 2010;7:281-287.
29. Werth N, Beerlage C, Rosenberger C, et al. Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. PLoS One 2010;5:e11576.
30. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med (Berl) 2007;85:1295-1300.
31. Giatromanolaki A, Sivridis E, Maltezos E, et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol 2003;56:209-213.
32. Kennedy A, Ng CT, Biniecka M, et al. Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum 2010;62:711-721.
33. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656-665.
34. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012;148:399-408.
35. Taylor CT. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J 2008;409:19-26.
36. Zinkernagel AS, Johnson RS, Nizet V. Hypoxia inducible factor (HIF) function in innate immunity and infection. J Mol Med (Berl) 2007; 85:1339-1346.
37. Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009;9:609-617.
38. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-657.
39. Walmsley SR, Print C, Farahi N, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med 2005;201:105-115.
40. Dang EV, Barbi J, Yang HY, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011;146:772-784.
41. Jantsch J, Chakravortty D, Turza N, et al. Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J Immunol 2008;180:4697-4705.
42. Naldini A, Morena E, Pucci A, et al. Hypoxia affects dendritic cell survival: role of the hypoxia-inducible factor-1alpha and lipopolysaccharide. J Cell Physiol 2012;227:587-595.
43. Vannay A, Sziksz E, Prokai A, et al. Increased expression of hypoxia-inducible factor 1alpha in coeliac disease. Pediatr Res 2010;68: 118-122.
44. Hirota SA, Fines K, Ng J, et al. Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. Gastroenterology 2010;139:259-69 e3.
45. Hart ML, Grenz A, Gorzolla IC, et al. Hypoxia-inducible factor-1alpha-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5'-nucleotidase (CD73) and the A2B adenosine receptor. J Immunol 2011;186:4367-4374.
46. Shah YM, Ito S, Morimura K, et al. Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology 2008;134:2036-2048, 48 e1-3.
47. Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch 2005;450:363-371.
48. Eltzschig H, Carmeliet P. Hypoxia and inflammation. N Engl J Med, 364:656-665.
49. Taylor CT, Cummins EP. The role of NF-kappaB in hypoxia-induced gene expression. Ann N Y Acad Sci 2009;1177:178-184.
50. Luo JL, Kamata H, Karin M. The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol 2005;25:541-550.
51. Hayden MS, NF-kappa B Ghosh S. The first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012;26: 203-234.
52. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-296.
53. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-472.
54. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-468.
55. Kaelin Jr WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402.
56. Greer SN, Metcalf JL, Wang Y, et al. The updated biology of hypoxia-inducible factor. EMBO J 2012;31:2448-2460.
57. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA. 2006;103: 18154-18159.
58. Takeda Y, Costa S, Delamarre E, et al. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 2011;479:122-126.
59. Chan DA, Kawahara TL, Sutphin PD, et al. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009;15:527-538.
60. Cummins EP, Seeballuck F, Keely SJ, et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 2008;134:156-165.
61. Robinson A, Keely S, Karhausen J, et al. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 2008; 134:145-155.
62. Hindryckx P, De Vos M, Jacques P, et al. Hydroxylase inhibition abrogates TNF-alpha-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. J Immunol 2010;185:6306-6316.
63. Hindryckx P, Staelens S, Devisscher L, et al. Longitudinal quantification of inflammation in the murine dextran sodium sulfate-induced colitis model using muPET/CT. Inflamm Bowel Dis 2010;17:2058-2064.
64. Edelblum KL, Yan F, Yamaoka T, et al. Regulation of apoptosis during homeostasis and disease in the intestinal epithelium. Inflamm Bowel Dis 2006;12:413-424.
65. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:362-381.
66. Tambuwala MM, Cummins EP, Lenihan CR, et al. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 2010; 139:2093-2101.
67. Louis NA, Hamilton KE, Kong T, et al. HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J 2005;19:950-959.
68. Synnestvedt K, Furuta GT, Comerford KM, et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110:993-1002.
69. Kong T, Westerman KA, Faigle M, et al. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 2006;20:2242-2250.
70. Louis NA, Hamilton KE, Canny G, et al. Selective induction of mucin-3 by hypoxia in intestinal epithelia. J Cell Biochem 2006; 99:1616-1627.
71. Furuta GT, Turner JR, Taylor CT, et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med 2001;193:1027-1034.
72. Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-3394.
73. Walmsley SR, Chilvers ER, Thompson AA, et al. Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. J Clin Invest 2011;121:1053-1063.